Radiotherapy and razoxane in advanced bile duct carcinomas

Anticancer Research

Volumn 25, Issue 5, 2005, Pages 3613-3618

  Rhomberg, Walter ^a,c   Stephan, Hans ^b   Bohler, Franz ^a   Erhart, Kurt ^b   Eiter, Helmut ^a  

^a Federal Academic Hospital   (Australia)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c GENERAL HOSPITAL   (Austria)

Author keywords

Bile duct carcinomas; Carcinoma of the gallbladder; Radiosensitizing agents; Razoxane

Indexed keywords

RADIOSENSITIZING AGENT; RAZOXANE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BILE DUCT CARCINOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG RESPONSE; EXTRAHEPATIC BILE DUCT CARCINOMA; FATIGUE; FEMALE; GALLBLADDER CARCINOMA; HUMAN; IATROGENIC DISEASE; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION INJURY; RADIATION RESPONSE; TASTE DISORDER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; COMBINED MODALITY THERAPY; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIATION-SENSITIZING AGENTS; RAZOXANE;

EID: 23344450013     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Bathe OF, Pacheco JT, Ossi PB et al: Management of hilar bile duct carcinoma. Hepatogastroenterology 48: 1289-1294, 2000.
2. McMasters KM, Tuttle TM, Leach SD et al: Neoadjuvant chemoradiation for extrahepatic cholangiocarcinoma. Am J Surg 174: 605-608, 1998.
3. Schoenthaler R, Phillips TL, Castro J et al: Carcinoma of the extrahepatic bile ducts. The University of California at San Francisco experience. Ann Surg 219: 267-274, 1994.
4. Shinchi H, Takao S, Nishida H, Aikou T: Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma. J Surg Oncol 75: 89-94, 2000.
5. Urego M, Flickinger JC and Carr BI: Radiotherapy and multimodality management of cholangiocarcinoma. Int J Radiat Oncol Biol Phys 44: 121-126, 1999.
6. Brunner T, Grabenbauer G, Strnad V et al: Nur Patienten mit kleinen irresektablen Tumoren der Gallenwege und der Gallenblase profitieren von einer simultanen Radiochemotherapie. Strahlenther Onkol Sondernr. 1, p 88, Abstract P 4.11, 2001.
7. De Vreede I, Steers JL, Burch PA et al: Prolonged disease-free survival after orthotopic liver transplantation plus additive chemoirradiation for cholangiocarcinoma. Liver Transpl 6: 309-316, 2000.
8. Kamada T, Saito H, Takamura A et al: The role of radiotherapy in the management of extrahepatic bile duct cancer: An analysis of 145 consecutive patients treated with intraluminal and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 34: 767-774, 1996.
9. Serafini FM, Sachs D, Bloomston M et al: Location, not staging, of cholangiocarcinoma determines the role for adjuvant chemoradiation therapy. Am Surg 67: 839-843, 2001.
10. Alden ME and Mohiuddin M: The impact of radiation dose in combined external beam and intraluminal Ir-192 brachytherapy for bile duct cancer. Int J Radiat Oncol Biol Phys 28: 945-951, 1994.
11. Ewing H, Sali A and Kune GA: Klatskin tumors: a 20 year experience. Aust N Z J Surg 59: 25-30, 1989.
12. Flickinger JC, Epstein AH, Iwatsuki S, Carr BI and Starzl TE: Radiation therapy for primary carcinoma of the extrahepatic biliary system. Cancer 68: 289-294, 1991.
13. Fritz P, Brambs HJ, Schraube P et al: Combined external beam radiotherapy and intraluminal high dose rate brachytherapy on bile duct carcinomas. Int J Radiat Oncol Biol Phys 29: 855-861, 1994.
14. Veeze-Kuijpers B, Meerwaldt JH, Lameris JS et al: The role of radiotherapy in the treatment of bile duct carcinoma. Int J Radiat Oncol Biol Phys 18: 63-67, 1990.
15. Fields JN and Emami B: Carcinoma of the extrahepatic biliary system - results of primary and adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 13: 331-338, 1987.
16. Kresl JJ, Schild SE, Henning GT et al: Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gallbladder carcinoma. Int J Radiat Oncol Biol Phys 52: 167-175, 2002.
17. Lameris JS, Hesselink EJ, Van Leeuwen PA et al: Ultrasound-guided percutaneous transhepatic cholangiography and drainage in patients with hilar cholangiocarcinoma. Semin Liver Dis 10: 121-125, 1990.
18. Saito H and Takamura A: Management of hilar bile duct carcinoma with high-dose radiotherapy and expandable metallic stent placement. Nippon Geka Gakkai Zasshi 101: 423-428, 2000.
19. van Gulik TM, Rauws EA, Gonzales-Gonzales D et al: Pre- and postoperative irradiation in the treatment of resectable Klatskins tumors. Ned Tijdschr Geneeskd 141: 1331-1337, 1997.
20. Verbeek PC, Van Leeuwen DJ, Van der Heyde MN and Gonzalez-Gonzalez D: Does additive radiotherapy after hilar resection improve survival of cholangiocarcinoma? An analysis in sixty-four patients. Ann Chir 45: 350-354, 1991.
21. Buskirk St, Gunderson LL, Adson MA et al: Analysis of failure following curative irradiation of gallbladder and extrahepatic bile duct carcinoma. Int J Radiat Oncol Biol Phys 10: 2013-2023, 1984.
22. Köster R and Scherer E: Present state and possibilities of radiotherapy in the interdisciplinary treatment of malignant tumours of stomach, pancreas and biliary tract. III. Extrahepatic bile ducts and gall bladder. Strahlenther 160: 403-410, 1984.
23. Minsky BD, Wesson MF, Armstrong J et al: Combined modality therapy of extrahepatic biliary system cancer. Int J Radiat Oncol Biol Phys 18: 1157-1163, 1990.
24. Hellmann K and Murkin GE: Synergism of ICRF 159 and radiotherapy in the treatment of experimental tumors. Cancer 34: 1033-1039, 1974.
25. Norpoth K, Schaphaus A, Ziegler H and Witting U: Combined treatment of the Walker tumor with radiotherapy and ICRF 159. Z Krebsf 82: 328, 1974.
26. Rhornberg W, Böhler F, Eiter H et al: Radiotherapy and razoxane in the palliative treatment of gastric cancer. Radiat Oncol Invest 4: 27-32, 1996.
27. Rhomberg W, Eiter H, Hergan K, Schneider B: Inoperable recurrent rectal cancer: results of a prospective trial with radiation therapy and razoxane. Int J Radiat Oncol Biol Phys 30: 419-425, 1994.
28. Bakowski MT: ICRF 159, +/- 1,2-di (3,5-dioxopiperazinyl)-propane; NSC 129943; razoxane. Cancer Treat Rev 3: 95-107, 1976.
29. Hellmann K and Rhornberg W: Radiotherapeutic enhancement by razoxane. Cancer Treat Rev 18: 225-240, 1992.
30. Atherton A: The effect of (+/-) 1,2-bis(3,5-dioxopiperazin-1-yl) propane (ICRF 159) on liver metastases from a hamster lymphoma. Eur J Cancer 11: 383-388, 1975.
31. Hellmann K and Burrage K: Control of malignant metastases by ICRF 159. Nature 224: 273-275, 1969.
32. Salsbury AJ, Burrage K and Hellmann K: Histological analysis of the antimetastatic effect of 1,2-bis (3,5-dioxo-piperazin-1-yl)-propane. Cancer Res 34: 843-849, 1974.
33. Karakiulakis G, Missirlis E and Maragoudakis ME: Mode of action of razoxane: inhibition of basement membrane collagen-degradation by a malignant tumor enzyme. Methods Find Exp Clin Pharmacol 11: 255-261, 1989.
34. Tanabe K, Ikegami Y, Ishida R et al: Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives. Cancer Res 51: 4903-4908, 1991.
35. Hendrickx P, Luska G, Junker D et al: Results of percutaneous transluminal irradiation of biliary tract carcinoma with 192 Iridium. Strahlenther Onkol 166: 392-396, 1990.
36. Milella M, Salvetti M, Cerrotta A et al: Interventional radiology and radiotherapy for inoperable cholangiocarcinoma of the extrahepatic bile ducts. Tumori 84: 467-471, 1998.
37. Gallardo J, Fodor M, Gamargo C et al: Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma (Correspondence). Cancer 83: 2419-2420, 1998.
38. Gebbia V, Macello E, Test A et al: Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-Fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Cancer 78: 1300-1307, 1996.
39. Patt YZ, Jones DV Jr, Hoque A et al: Phase II trial of intravenous fluorouracil and subcutaneous Interferon alpha-2b for biliary tract cancer. J Clin Oncol 14: 2311-2315, 1996.
40. Sanz-Altamira PM, Ferrante K, Jenkins RL et al: A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82: 2321-2325, 1998.
41. Morganti AG, Trodella L, Valentini V et al: Combined modality treatment in unresectable extrahepatic biliary carcinoma. Int J Radiat Oncol Biol Phys 46: 913-919, 2000.
42. Robertson JM, Lawrence TS, Dworzanin LM et al: Treatment of primary hepatobiliary cancers with conformal radiation therapy and regional chemotherapy. J Clin Oncol 11: 1286-1293, 1993.
43. Glade-Bender J, Kandel JJ and Yamashiro DJ: VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3: 263-276, 2003.
44. Rhomberg W, Hassenstein EOM and Gefeller D: Radiotherapy vs. radiotherapy and razoxane in the treatment of soft tissue sarcomas: final results of a randomized study. Int J Radiat Oncol Biol Phys 36: 1077-1084, 1996.
45. Hatano K, Cho K, Okamoto M et al: Results of radiation therapy of extrahepatic bile duct carcinoma. Nippon Igaku Hoshasen Gakkai Zasshi 52: 799-803, 1992.
46. Hayes JK, Sapozink MD, Miller FJ: Definitive radiation therapy in bile duct carcinoma. Int J Radiat Oncol Biol Phys 15: 735-744, 1988.
47. Kurosaki H, Karasawa K, Kaizu T et al: Intraoperative radiotherapy for resectable extrahepatic bile duct cancer. Int J Radiat Oncol Biol Phys 45: 635-638, 1999.
48. Kuvshinoff BW, Armstrong JG, Fong Y et al: Palliation of irresectable hilar cholangiocarcinoma with biliary drainage and radiotherapy. Br J Surg 82: 1522-1525, 1995.
49. Vallis KA, Benjamin IS, Munro AJ et al: External beam and intraluminal radiotherapy for locally advanced bile duct cancer: role and tolerability. Radiother Oncol 41: 61-66, 1997.